key: cord-0807993-ccn6xky8
authors: Dispinseri, S.; Secchi, M.; Pirillo, M. F.; Tolazzi, M.; Borghi, M.; Brigatti, C.; De Angelis, M. L.; Baratella, M.; Bazzigaluppi, E.; Venturi, G.; Sironi, F.; Canitano, A.; Marzinotto, I.; Tresoldi, C.; Ciceri, F.; Piemonti, L.; Negri, D.; Cara, A.; Lampasona, V.; Scarlatti, G.
title: COVID-BioB Cohort Study: the neutralizing antibody response to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for virus control and survival.
date: 2021-02-19
journal: nan
DOI: 10.1101/2021.02.17.21251929
sha: 54253d7967be6cd16727efcc64b49c282933c1fe
doc_id: 807993
cord_uid: ccn6xky8

Understanding how antibody to SARS-CoV-2 evolve during infection may provide important insight into therapeutic approaches to prevent fatal COVID-19 illness and vaccines. Here, we profile the antibody response of 162 well-characterized COVID-19 symptomatic patients followed longitudinally for up to eight months from symptom onset. Using two newly developed assays we detect SARS-CoV-2 neutralization and antibodies binding to Spike antigens and nucleoprotein as well as to Spike S2 antigen of seasonal beta-coronaviruses, and to hemagglutinin of the H1N1 flu virus. Presence of neutralizing antibodies withing the first weeks from symptom onset correlates with time to a negative swab result (p=0.002) while lack of neutralization with an increased risk of a fatal disease outcome (HR 2.918, 95%CI 1.321-6.449; p=0.008). Neutralizing antibody titers progressively drop after 5-8 weeks but are still detectable up to 8 months in the majority of recovered patients regardless of age or co-morbidities. IgG to Spike antigens are the best correlate of neutralization. Antibody responses to seasonal coronaviruses are temporary boosted and parallel those to SARS-CoV-2 without dampening the specific response or worsening disease progression. Thus, a compromised immune response to the Spike rather than an enhanced one is a major trait of patients with critical conditions. Patients should be promptly identified and immediately start therapeutic interventions aimed at restoring their immunity.

The outcome of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection while mild in the majority of infected individuals, is severe in a significant proportion, requiring hospitalization, and fatal in a minority. 1 The SARS-CoV-2 antibody response has been studied in large cohorts of infected individuals with diverse Corona Virus Disease 19 severity. Antibodies to the Spike's receptor binding domain (RBD) appear within the first three weeks from symptoms onset and IgG and/or IgA seroconversion occur either sequentially or simultaneously with the appearance of IgM. 2,3 Using a newly developed Luciferase Immunoprecipitation System (LIPS) assay to detect antibodies to SARS-CoV-2 antigens, we showed that 95% of 509 COVID-19 patients developed IgG by week four from symptom onset and further rose until the third month of follow-up. 4 Also, the presence of RBD IgG in the earliest available sample correlated with survival while that of whole Spike IgA correlated with time to a virus negative naso-pharyngeal swab by RT-PCR.

in vitro and thwart viral replication in vivo. Indeed, clinical trials with monoclonal nAb (mAb) against SARS-CoV-2 RBD, decreased viral load in patients with recently diagnosed mild/moderate COVID-19, [5] [6] [7] suggesting that a native nAbs response could have a major impact on the disease if induced early after infection. However, there is still controversy on the impact of nAbs, with some early studies even suggesting a detrimental role on disease progression, 8, 9 while more recent data showed no differences in nAbs early after infection in hospitalized patients with diverse disease outcome. 3 Moreover, data on the closely related MERS and SARS-CoV beta-coronaviruses suggest that humoral immunity, while still detectable beyond one year after hospitalization, wanes over time. 10, 11 Whether SARS-CoV-2 nAbs decline at a similar pace is yet to be established conclusively considering the current timing of the pandemic. As of today, most published serological studies are mainly cross-sectional or at the most include a longitudinal follow-up of few months. 3, [12] [13] [14] Here we provide a comprehensive antibody profile of well-characterized COVID-19 symptomatic patients followed longitudinally for up to eight months from symptom onset. We tested 162 patients using a newly developed, robust lentiviral vector (LV)-based SARS-CoV-2 neutralization assay and our LIPS assay for the detection of IgG, IgM and IgA to SARS-CoV-2 Spike, RBD and nucleoprotein (NP) All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted February 19, 2021. ;  https://doi.org/10.1101/2021.02.17.21251929 doi: medRxiv preprint 5 as well as to Spike of seasonal beta-coronaviruses, and to H1N1 influenza virus hemagglutinin. Our results indicate that early development of nAbs is critical for patient survival and virus control, supporting the introduction of mAb therapy early on after infection in selected patients and that the induction of protective nAbs by prophylactic vaccination is likely durable.

All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in 

We studied 162 patients with confirmed SARS-CoV-2 infection enrolled from February 25 th , 2020 in the COVID-19 clinical-biological cohort study (COVID-BioB) at the IRCCS San Raffaele Hospital (ClinicalTrialsgov-NCT04318366) as previously described (Supplementary Materials, SM). 15 Biological material for COVID-BioB included a dedicated serum sample collected at hospital attendance (inhospital sample) either in the Emergency Department (ED) or the ward and follow-up samples collected in the out-patient clinic at planned 1, 3 and 6 months visits post-discharge. An in-hospital sample was available for 150 patients, while follow-up samples were available for 87 patients at the 1 month visit, 77 patients at the 3 month visit, and 46 patients at the 6 months visit (table 1) . Twelve patients with no history of hospital admission were followed at the out-patient clinic for up to five visits.

Antibodies were measured by LIPS assays. 4 We expressed by transient transfection into Expi293F™ cells (Thermo Fisher Scientific, Waltham, MA, USA) several recombinant viral antigens tagged with a Nanoluciferase reporter (Promega, Madison, Wisconsin, USA) as described in SM and figure S2. Each antigen was incubated in liquid phase with test serum (1ul) for 2 h, followed by immune-complexes capture with rProtein A-sepharose and measurement of recovered luciferase activity in a XS960 Centro luminometer (Berthold). Using positive sera as standards, raw data was then converted into arbitrary units (AU).

LV expressing Luciferase (LV-Luc) pseudotyped with a membrane tethered Spike protein, either full length or with a 21 aminoacid truncated cytoplasmic tail (C3), or the VSV.G glycoprotein were produced by transient transfection of 293T Lenti-X cells with transfer vector plasmid pGAE-LucW, packaging plasmid pADSIV3+ and pseudotyping plasmid (pSpike, pSpike-C3 or phCMV-VSV.G) as detailed in SM. LV-Luc preparations were titered on VeroE6 cells and dilutions providing 150,000-200,000 RLU were used in the neutralization assay. Serum serial 3-fold dilutions starting from the 1/40 dilution were incubated in duplicate with the LV-Luc for 30 min at 37°C in 96-well plates, and thereafter added to VeroE6 cells. After 48 h luciferase expression was determined with a luciferase assay system (Bright-Glo, Promega) and measured in a Mitras luminometer (Berthold). Inhibitory serum dilution (ID) 50 was calculated with a linear interpolation method. 16 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in 

Median with either 95% CI, range, or inter-quartiles range (IQR) in parenthesis and frequency or percent were used to report continuous variables and categorical variables, respectively. Chi-square or Fischer's exact test were used to compare categorical variables. Wilcoxon rank sum or Kruskal-Wallis test were used to compare continuous variables. Imputation for missing data was not performed. Timeto-event was calculated from the date of symptom onset to the date of death, or of last follow up visit, whichever occurred first. Survival was estimated according to Kaplan-Meier. Association between antibody positivity and time to death was calculated using univariate and multivariate Cox proportional hazards models. The effect was reported as hazard ratio (HR) with the corresponding 95% CI, estimated using the Wald approximation. All survival analysis and association were stratified according to time from the onset of symptoms to blood sampling (weeks 1, 2, 3, ≥ 4). Two-tailed p values are reported, with p value <0.05 indicating statistical significance. All confidence intervals are two-sided and not adjusted for multiple testing. Statistical analyses were performed with SPSS 24 (SPSS Inc./IBM) and the R software version 3.4.3. 17

The sponsors had no role in study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication. All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in 

We profiled the humoral immune response of 162 patients of our COVID-BioB cohort. All had a confirmed SARS-CoV-2 infection and a record of symptoms onset. Serum samples were collected at hospital admission in March-April and at the out-patient visits during follow-up until Nov 25, 2020 (table   1) . Patients were predominantly Caucasian (89.5%), male (66.7%) and had a median age of 63 years.

A relevant fraction had a body mass index >30 (32.4%) and 57.4% had one or more co-morbidity, with hypertension (44.4%) and diabetes (24.7%) being the most frequent (table 2). Patients sought an emergency hospital visit after a median of nine days from symptoms onset and 134 were hospitalized.

At admission, symptoms consisted prevalently of fever, fatigue and respiratory difficulties often associated with dyspnea. The median hospitalization duration was 14 days. Overall, 26 patients entered the Intensive Care Unit (ICU) and 29 passed away, of whom 11 after ICU entry. The median time to a negative RT-PCR results of the naso-pharyngeal swab was 40 days (IC95% 37-43). Patients who recovered were followed-up for a median of 201 days (range 145-250) from symptom onset. The set of laboratory blood tests recorded as per COVID-BioB protocol is presented in table S1 and SM. The general characteristics of this study cohort reflect those of the overall COVID-19 patients admitted to our hospital during the same period and previously described. 4, 15 Truncated Spike on LV pseudovirions improves infectivity and is suitable for SARS-CoV-2 neutralization assay To test the nAb response, we developed and optimized a Lentiviral (LV)-based SARS-CoV-2 neutralization assay, suitable for handling in a Biosafety Level 2 environment. This assay is based on Luciferase expressing LV (LV-Luc) pseudoparticles, enveloped with a Spike glycoprotein containing a 21aa deletion in the cytoplasmic tail (Spike-C3) (SM, figure S1 ). This truncation removes an endoplasmic reticulum (ER) retention signal that interferes with the budding of viral particles, 18, 19 thus favoring the interaction of Spike and Gag proteins during particle assembly. 20 Upon transfection into 293T Lenti-X cells of either full-length Spike or Spike-C3 expression plasmids, both constructs showed comparable expression levels on the cell surface ( figure 1A ). Conversely Spike-C3 was incorporated on the pseudoparticles' surface at higher levels than the whole Spike, though Gag protein content was comparable across all preparations (figure 1B). All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in 10 204 days, range 145-250). In these patients nAb titers were further decreasing (median ID50 1/660, range 1/<40-10,900), but no additional patient lost the nAb response. In 26 non-hospitalized patients, despite a less severe disease, the profile of nAbs and anti-Spike antibodies was similar to that of hospitalized patients (figure S8, SM). Overall, 67.3% (101/150) COVID-19 patients developed nAbs rapidly within 2 weeks from symptoms onset, which persisted up to 36 weeks in all but three patients.

As expected, IgM and IgA to SARS-CoV-2 antigens, measured up to eight weeks from symptoms onset, progressively declined during follow-up (figures 3B-C). The kinetic of IgG response to Spike proteins reflected that of nAbs (figure 2, table S2): antibodies to S1+S2 reached a peak by 5-8 weeks and then declined, while those to RBD and S2 continued to rise throughout follow-up, but still correlated (table S3) , while significantly correlated with critical illness ( figure   S4 ). Importantly, lack of a nAb response early after infection was a strong predictor of death when stratified for time from symptoms and corrected for age and sex (HR 2.918, 95%CI 1.321-6.449; p=0.008) (figure 4B). This correlation was still maintained if we applied more stringent ID75 (HR=2.67 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in (1.2-5.9), p=0.015). In addition, the correlation was further maintained when corrected for each one of the identified correlates of death, including co-morbidities and relevant immune-inflammatory markers, and the absence of IgA to S1+S2 (figure S5).

Kinetics and persistence of neutralizing antibodies is preserved despite advanced age and comorbidities We investigated also the impact of advanced age and diverse co-morbidities on nAb response' kinetics (table S3). In patients above 63 years of age or presenting one or more co-morbidities and who passed away, we detected low or no nAbs in the first weeks after symptoms onset (figure 5). Patients without an early nAb response were significantly older with debilitating co-morbidities, including cancer or chronic pulmonary and kidney diseases. Noteworthy, these patients presented frequently a disease onset with less severe COVID-related respiratory symptoms that did not require ICU admission, and clinical laboratory tests mostly showing a lower immune-inflammatory activation with organ involvement. Conversely, in patients who recovered, advanced age and presence of co-morbidities did not impact on the distribution of early antibody response and, analogously, titre, kinetics and persistence of nAbs after recovery were not affected by either parameter.

Antibody responses to seasonal coronaviruses are temporary boosted without worsening disease progression Pre-existing antibody responses to other beta-coronaviruses have been proposed to potentially have either a detrimental or beneficial role in COVID-19. 21, 22 Testing of IgG to S2 of HCoV-OC43 and -HKU1 in samples collected during the first weeks from symptoms onset did not correlate with either time to a negative swab test or death ( figure S4 ). However, in the same time window, IgG titers to S2 of HKU1 and OC43 correlated with SARS-CoV-2 nAb titers (figures 6A, S6). Interestingly, patients who developed nAbs to SARS-CoV-2 during the first three weeks from symptoms onset had significantly higher IgG titers to either HCoVs compared to patients with undetectable nAbs, a difference that IgG responses but not with nAbs in COVID-19 patients. 3 Previous reports raised doubts as to the efficacy of the protection conferred by nAbs in severe COVID-19 and suggested that enhanced nAbs might correlate with a negative clinical outcome. [12] [13] [14] Conversely, in our study an absent nAb response early after disease onset, more than a difference in titre, was the strongest correlate with both death and delayed viral control. Aware that our patient cohort was characterized by an advanced age and diverse co-morbidities, we evaluated their impact on nAb kinetics. Indeed, the patients that did not develop nAbs were mostly elderly men (median age 74 years, range 59-79) with chronic severe comorbidities. However, upon controlling for these factors, we confirmed that a compromised immune response to the Spike (rather than an enhanced one) is a major trait of patients with critical conditions. Conversely, patients with nAbs and anti-Spike IgA showed a faster control of the virus. Importantly, anti-Spike binding antibodies correlated with nAbs, confirming their potential usefulness as proxy biomarkers of a nAb response.

Recent data suggest that a cocktail of virus-specific mAbs was more efficient in reducing the viral load in symptomatic out-patients with high viral load but as yet no IgG and IgA response. 5 Similarly, plasma with high titer nAbs administered to elderly patients within 3 days after symptoms onset reduced the risk of progression to severe respiratory disease. 6 Currently, the Food and Drug Administration has granted an emergency use authorization for the virus-specific mAb therapy only for out-patients with mild-moderate COVID-19. 23 Considering that elderly males with chronic co-morbidities are extremely vulnerable to severe COVID-19 in the absence of an anti-Spike response, we believe that these patients All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in 13 should be promptly identified and immediately start therapeutic interventions aimed at restoring the lack of a functional humoral immunity.

Interestingly, our data show that a pre-existing immunity to seasonal HCoVs may favour early and increased responses to SARS-CoV-2. In contrast with Aydillo et al. and in agreement with Anderson et al., 21, 22 that analyzed smaller cohorts over a shorter time span, we found no correlation between the expansion of IgG to HCoVs and a delayed development of SARS-CoV-2 specific antibodies. In fact, our patients exhibited a back-boosting of antibodies to OC43 and HKU1 S2. This is hardly surprising in light of the structural and partial sequence homology (approximately 40%) between SARS-CoV-2 and HCoVs S2 domains. Indeed, the correlation of nAb titers with the IgG responses to seasonal betacoronaviruses was good in the first weeks from disease onset, although invariably less than that with SARS-CoV-2 Spike IgG. However, with our LV-based assay we excluded that HCoV-S2 IgG positive, but SARS-CoV-2 Spike IgG negative sera neutralize SARS-CoV-2. Thus, if IgG to HCoV S2 are indeed cross-reactive to SARS-CoV-2 they are likely of low affinity and non-neutralizing but may possibly mediate a phenomenon of antibody dependent enhancement. This suggests that a pre-existing strong immunity to other beta-coronaviruses may in fact favour, more than deviate, an early nAb response to SARS-CoV-2.

As generally expected after the resolution of a viral infection, in our study nAbs started to drop in recovered patients after 5-8 weeks from symptoms onset. Nevertheless, in all but three patients nAbs above the assay threshold persisted for as long as eight months. Neither COVID-19 severity at disease onset, nor age, nor the presence of multiple co-morbidities affected the kinetics and persistence of nAbs. At the last follow-up visit, the distribution of nAbs titre was wide and spanning four orders of magnitude starting from close to the assay threshold. However, regardless of presence of long-term detectable antibodies, infection and vaccination will induce a memory B-cell response, 14,24 that might rapidly mount a specific humoral response. At the third follow-up visit in nine of the 42 nAb-positive COVID-19 patients we documented a major increase of nAb titre (up to 400%) paralleled by levels of IgG to Spike antigens (figure S7). We cannot conclusively state that this raise was due to a re-exposure to SARS-CoV-2 since none of the patient declared any COVID-related symptoms nor was a virus detection test performed. However, the time of sampling during follow-up of these patients overlapped with the second epidemic wave in Italy. 25 We can speculate that if indeed a re-exposure to the virus All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted February 19, 2021. ; https://doi.org/10.1101/2021.02.17.21251929 doi: medRxiv preprint occurred, followed by either an asymptomatic or aborted re-infection, then the boost of their antibody levels hints to a responsive adaptive immune system with the ability to control the disease.

While regular re-exposure may sustain protective antibodies, this is based on the predicament that new resistant viral variants will not arise. Although new variants are circulating already world-wide, the impact of the Spike/RBD mutations has still to be defined. 26 All authors reviewed the manuscript for intellectual content and assisted in data interpretation.

VL, GS, DN, AC, SD prepared the manuscript for submission.

All authors confirm that they had full access to all the data in the study and accept responsibility to submit for publication. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in Special acknowledement goes to the COVID-BioB team # and healthcare workers at OSR that made this work possible.

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation, with publication.

All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in For each pair, the Pearson's correlation coefficient is shown as number and on a color scale.

Statistically non-significant correlations are crossed. All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in Raincloud plot of each patient's nAb response (circles) expressed as the reciprocal of the ID50 titer.

Patients are stratified by time from symptoms onset at sampling (vertical panels, weeks) and clinical outcome (recovered or deceased). Patients are further stratified as below or above the median age of the overall study population (<63 years = blue, >63 years = red ) or according to the presence of any co-morbidity (present = red, absent = blue). Shown are the probability density estimate (with the half violin plot upscaled to maximum width for better visualization) and box plots displaying median, IQR, and whiskers extending to 1.96 times the IQR. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in skin rash 6%

Median days (95%CI) from symptoms onset: 0 -to admission (n=150) 9 (5-12)

-to first blood sampling for Biobank 11.5 (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) Median hospital stay, days (N=134) 14 (7-24) 0

Median days (95%CI) from symptoms to negative RT-PCR swab 40 (37-43) 7

Median follow-up days (95%CI) (N= 162) 201 (196-205) 0

All rights reserved. No reuse allowed without permission.

perpetuity.

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in 

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention

Antibody responses to SARS-CoV-2 in patients with COVID-19

Compromised Humoral Functional Evolution Tracks with SARS-CoV-2 Mortality

COVID-19 survival associates with the immunoglobulin response to the SARS-CoV-2 spike Receptor Binding Domain

REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19

Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19

Evaluating the Association of Clinical Characteristics With Neutralizing Antibody Levels in Patients Who Have Recovered From Mild COVID-19 in

Neutralizing Antibody Responses to Severe Acute Respiratory Syndrome Coronavirus 2 in Coronavirus Disease

Longitudinally profiling neutralizing antibody response to SARS coronavirus with pseudotypes

MERS-CoV antibody responses 1 year after symptom onset, South Korea

Longitudinal Dynamics of the Neutralizing Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection

Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

Biobanking for COVID-19 research

International network for comparison of HIV neutralization assays: The NeutNet report

R: A Language and Environment for Statistical Computing

Retroviral vectors pseudotyped with severe acute respiratory syndrome coronavirus S protein

Cytoplasmic tail of coronavirus spike protein has intracellular targeting signals

Incorporation of High Levels of Chimeric Human Immunodeficiency Virus Envelope Glycoproteins into Virus-Like Particles

Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection

COVID-19) Update: FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19

Evolution of Antibody Immunity to SARS-CoV-2

Footnote to Table 1: a dedicated serum sample was collected during attendance at the hospital, which took place either at the ED or at the ward (called the in-hospital sample). Follow-up serum samples were collected at the COVID19 out-patient clinic during the one month, 3 and 6 months visits after discharge

All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in